ALXN MACD
As of date:7/21/2021
ALXN stock price:182.50
ALXN 50 DMA:179.76
ALXN 200 DMA:154.09
ALXN MACD (200-50):-25.67

Also see:
ALXN Market Cap History
ALXN Shares Outstanding History
ALXN YTD Return
ALXN DMA
ALXN RSI
ALXN Technical Analysis

Try ChartSweeps today

APPF Makes Bullish Cross Above Critical Moving Average
1 hour, 17 minutes ago


Bullish Two Hundred Day Moving Average Cross - TOI
1 hour, 17 minutes ago


IRBT Makes Bullish Cross Above Critical Moving Average
1 hour, 19 minutes ago


Swk Holdings Breaks Above 200-Day Moving Average - Bullish for SWKH
1 hour, 30 minutes ago


Bullish Two Hundred Day Moving Average Cross - GNOM
1 hour, 31 minutes ago


Trinet Group (TNET) Shares Cross Above 200 DMA
1 hour, 31 minutes ago


Hannon Armstrong Sustainable Infrastructure Capital Breaks Above 200-Day Moving Average - Bullish for HASI
1 hour, 39 minutes ago


BlackRock Multi-Sector Income Trust Breaks Above 200-Day Moving Average - Bullish for BIT
1 hour, 43 minutes ago


FNK Crosses Above Key Moving Average Level
1 hour, 43 minutes ago


Invesco Zacks Mid-Cap Breaks Above 200-Day Moving Average - Bullish for CZA
1 hour, 43 minutes ago


Bullish Two Hundred Day Moving Average Cross - CII
1 hour, 43 minutes ago


Bullish Two Hundred Day Moving Average Cross - DFEB
1 hour, 56 minutes ago


Bullish Two Hundred Day Moving Average Cross - DSTL
1 hour, 59 minutes ago


SPDR Russell 1000 Low Volatility Focus Breaks Above 200-Day Moving Average - Bullish for ONEV
2 hour ago


SPDR Russell 1000 Yield Focus (ONEY) Shares Cross Above 200 DMA
2 hour ago


More Technical Analysis News

ALXN MACDALXN DMA
Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. Co. has developed and commercializes two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. Co. also has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.

When researching a stock like Alexion Pharmaceuticals, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from ALXN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for ALXN stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the ALXN 200 day moving average ("ALXN 200 DMA"), while one of the most popular "shorter look-backs" is the ALXN 50 day moving average ("ALXN 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Alexion Pharmaceuticals. Comparing two moving averages against each other can be a useful visualization tool: by calculating the difference between the ALXN 200 DMA and the ALXN 50 DMA, we get a moving average convergence divergence indicator ("ALXN MACD"). The ALXN MACD chart, in conjunction with the chart of the moving averages, basically helps in visualizing how the moving averages are showing convergence (moving closer together), or divergence (moving farther apart).
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quotes delayed 20 minutes

Email EnvelopeFree ALXN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
 

ALXN MACD | www.StockMACD.com | Copyright © 2019 - 2022, All Rights Reserved

Nothing in StockMACD.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.